HC Wainwright Reaffirms Neutral Rating for Kezar Life Sciences (NASDAQ:KZR)

HC Wainwright reissued their neutral rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research report report published on Wednesday morning, MarketBeat.com reports.

Kezar Life Sciences Trading Down 3.4 %

KZR opened at $0.80 on Wednesday. Kezar Life Sciences has a 12 month low of $0.52 and a 12 month high of $1.14. The stock has a fifty day moving average price of $0.61 and a 200-day moving average price of $0.70. The firm has a market cap of $58.06 million, a price-to-earnings ratio of -0.57 and a beta of 0.20. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. As a group, equities research analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fidelis Capital Partners LLC acquired a new position in shares of Kezar Life Sciences during the first quarter valued at about $25,000. Mackenzie Financial Corp acquired a new position in Kezar Life Sciences during the 2nd quarter valued at approximately $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences in the second quarter worth $63,000. Marquette Asset Management LLC acquired a new stake in shares of Kezar Life Sciences during the first quarter worth $114,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after buying an additional 71,543 shares during the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.